Cargando…

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a common complication in chronic kidney disease (CKD) patients. Cinacalcet could be a therapeutic option although its use is controversial in patients not receiving dialysis. Thus, the aim of this study is to assess the effectiveness and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Ricart, Ariadna, Galicia-Basart, Maria, Alcalde-Rodrigo, Maria, Segarra-Medrano, Alfons, Suñé-Negre, Josep-Maria, Montoro-Ronsano, José-Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010289/ https://www.ncbi.nlm.nih.gov/pubmed/27588942 http://dx.doi.org/10.1371/journal.pone.0161527

Ejemplares similares

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Behets, Geert J, et al.
Publicado: (2015)

Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2018)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
por: Zitt, Emanuel, et al.
Publicado: (2013)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series
por: Ohri, Alpana, et al.
Publicado: (2022)

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review
por: Li, Xiaosong, et al.
Publicado: (2023)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas
por: Sugi, Orie, et al.
Publicado: (2010)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Otsuka, Keiichi, et al.
Publicado: (2018)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
por: Ng, Cheng Han, et al.
Publicado: (2020)

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
por: Timmons, J. G., et al.
Publicado: (2021)

Successful Early Treatment of Severe Neonatal Hyperparathyroidism With Cinacalcet
por: Thakkar, Keya, et al.
Publicado: (2021)

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
por: Meola, Mario, et al.
Publicado: (2009)

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
por: Nakayama, Kazunori, et al.
Publicado: (2013)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2019)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Successful treatment of neonatal severe hyperparathyroidism with cinacalcet in two patients
por: Fisher, Marisa M, et al.
Publicado: (2015)

Cinacalcet: A Viable Therapeutic Option for Primary Hyperparathyroidism in the Elderly
por: Abusahmin, Hussam, et al.
Publicado: (2018)

Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis
por: Dulfer, R. R., et al.
Publicado: (2019)

The conundrum of parathyroidectomy vs cinacalcet for treatment of post-transplant hyperparathyroidism
por: Patel, Rima, et al.
Publicado: (2020)

Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
por: Conzo, Giovanni, et al.
Publicado: (2012)

Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism
por: Evans, Marie, et al.
Publicado: (2018)

Cinacalcet is effective in the treatment of hyperparathyroidism secondary to malignant transformation of autotransplanted parathyroid tissue. A case report
por: Dattolo, Pietro, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_l77ei4j4ilu2b4glfojgr54rl9